Janux Therapeutics: Pay

Janux Therapeutics paid its 5 named executives $32.2M in total in FY2025 (Dec). CEO David Campbell, Ph.D. was paid $13.5M of that.

Pay$100 in the stock at the end of FY21 → $70
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

David Campbell, Ph.D.President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Byron Robinson, Ph.D., J.D.Former Chief Strategy Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Janeen DoyleChief Corporate and Business Development Officer
FY2025 (Dec)
1 year
Zachariah McIver, D.O., Ph.D.Former Chief Medical Officer
FY2025 (Dec)
1 year
Thomas DiRaimondo, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years

CEO pay against the pay peers

No CEO pay of the disclosed peers is on file for FY2024 (Dec).

  1. 1Janux Therapeutics
  2. 2Alaunos Therapeutics, IncNot disclosed
  3. 3Arcus BioSciences, Inc.Not disclosed
  4. 4Arvinas, Inc.Not disclosed
  5. 5BioAtla, Inc.Not disclosed
  6. 6Cue Biopharma, Inc.Not disclosed
  7. 7CytomX Therapeutics, Inc.Not disclosed
  8. 8Inhibrx Biosciences, Inc.Not disclosed
  9. 9Kura Oncology, Inc.Not disclosed
  10. 10Mersana Therapeutics, Inc.Not disclosed
  11. 11Poseida Therapeutics, Inc.Not disclosed
  12. 12Replimune Group, Inc.Not disclosed
  13. 13Sutro Biopharma, Inc.Not disclosed
  14. 14Syndax PharmaceuticalsNot disclosed
  15. 15Xencor, Inc.Not disclosed
  16. 16Zymeworks Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.